低剂量白介素2治疗中重度大疱性类天疱疮的疗效与安全性:单中心视角对照试验
结论支持低剂量白介素2可能使中重度大疱性类天疱疮患者更早出现治疗反应。
要点
- 低剂量白介素2联合糖皮质激素可缩短中重度大疱性类天疱疮达到疾病控制的时间。
- 治疗组全身糖皮质激素累计用量较少,且未检测到严重感染。
- 研究为单中心、开放标签、短疗程、小样本,结论需谨慎解读。
核心结论
- 低剂量白介素2治疗中重度大疱性类天疱疮显示出更早的治疗反应潜力。
研究设计与样本
- 单中心视角对照试验,共纳入43例中重度大疱性类天疱疮患者。
主要发现
- 治疗组全身糖皮质激素总量更少,且未检测到严重感染。
关键数值与推荐
- 主要结局为达到疾病控制所需天数。
- 次要结局包括其他临床反应。
临床怎么用
- 对于中重度大疱性类天疱疮患者,在糖皮质激素治疗基础上可考虑加用低剂量白介素2以可能加快疾病控制。
局限性
- 单中心、开放标签研究,疗程短且样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regulatory T cells (Tregs) are reduced in the peripheral blood and skin lesions of patients with bullous pemphigoid (BP). Low-dose interleukin 2 (IL-2) therapy can stimulate Tregs specifically, suggesting potential for the treatment of BP. OBJECTIVE: To evaluate the response to low-dose IL-2 therapy in the treatment of moderate-to-severe BP. METHODS: Forty-three patients with moderate-to-severe BP were included. The therapy included systemic corticosteroids with an initial dose of 0.5 mg/kg/d for moderate and 1.0 mg/kg/d for severe disease, respectively, combined with allowed immunosuppressants for the control group, whereas in addition to the same corticosteroid therapy, IL-2 (half million IU) was administered subcutaneously every other day for the treatment group for 8 weeks. The primary outcome was the number of days required to achieve disease control. Secondary outcomes included other clinical responses. RESULTS: The number of days required to achieve disease control with the treatment group was (7.60 ± 3.00), which was shorter than in the control group (10.43 ± 3.06) (P = .008). The total amount of systemic corticosteroids was less, and no serious infections were detected in the treatment group. LIMITATIONS: Single center, open-label study with short duration and small size. CONCLUSION: Our trial supports the potential of low-dose IL-2 therapy for patients with moderate-to-severe BP, which showed earlier treatment responses.
引用
- Xue R, Li G, Zhou Y, et al. Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. J Am Acad Dermatol. 2024. PMID: 39182680. doi:10.1016/j.jaad.2024.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。